DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cashman, J. R.
Right arrow Articles by Braun, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cashman, J. R.
Right arrow Articles by Braun, A.

Vol. 29, Issue 12, 1629-1637, December 2001

Population Distribution of Human Flavin-Containing Monooxygenase Form 3: Gene Polymorphisms

John R. Cashman, Jun Zhang, James Leushner, and Andreas Braun

Human BioMolecular Research Institute, San Diego, California (J.R.C., J.Z.); and Sequenom Incorporated, San Diego, California (J.L., A.B.)

The N-oxygenation of amines by the human flavin-containing monooxygenase (form 3) (FMO3) represents an important means for the conversion of lipophilic nucleophilic heteroatom-containing compounds into more polar and readily excreted products. Certain mutations of the human FMO3 gene have been linked to abnormal drug or chemical metabolism. For example, abnormal N-oxygenation of trimethylamine has been shown to segregate with mutations of human FMO3. To date, however, it is not known whether there is a pharmacogenetic basis for abnormal drug metabolism by human FMO3. The objective of this study was to estimate the allele and genotype frequencies at three variable DNA sites in the FMO3 gene in male and female blood bank donors representative of non-Hispanic Caucasians, non-Hispanic African Americans, Hispanics, and Asians sampled from the United States. The common polymorphisms at variable sites 158, 257, and 308 were experimentally determined using a high-throughput chip-based genotype variation detection method combining MassEXTEND and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. We also compared the genetic variation of nonhuman primate FMO3 with the human FMO3 gene. Exon sequence analysis of the monkey FMO3 gene sequence showed that it was similar to the human gene sequence but differed from the human consensus sequence at 31 fixed positions. Compared with that of human, the chimpanzee exon sequence had one polymorphism that induced an amino acid change. The evolutionary history of the FMO3 gene was inferred from the pattern of haplotype relationships across different populations and species. Statistically significant heterogeneity in the relative frequencies of single and multiple site alleles, haplotypes, and genotypes of the human FMO3 among ethnic subdivisions suggests that population differences in the susceptibility of humans to abnormal metabolism or adverse drug reactions for chemicals metabolized by human FMO3 could exist.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. Shimizu, H. Yano, S. Nagashima, N. Murayama, J. Zhang, J. R. Cashman, and H. Yamazaki
Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on N- and S-Oxygenation Activities
Drug Metab. Dispos., March 1, 2007; 35(3): 328 - 330.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. B. Koukouritaki, M. T. Poch, M. C. Henderson, L. K. Siddens, S. K. Krueger, J. E. VanDyke, D. E. Williams, N. M. Pajewski, T. Wang, and R. N. Hines
Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 266 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman
Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3
Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. A. Bain, R. Faull, G. Fornasini, R. W. Milne, and A. M. Evans
Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis
Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1300 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. M. Hisamuddin, M. A. Wehbi, A. Chao, H. W. Wyre, L. M. Hylind, F. M. Giardiello, and V. W. Yang
Genetic Polymorphisms of Human Flavin Monooxygenase 3 in Sulindac-Mediated Primary Chemoprevention of Familial Adenomatous Polyposis
Clin. Cancer Res., December 15, 2004; 10(24): 8357 - 8362.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. N. Hines, Z. Luo, K. A. Hopp, E. T. Cabacungan, S. B. Koukouritaki, and D. G. McCarver
Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1210 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Lattard, J. Zhang, Q. Tran, B. Furnes, D. Schlenk, and J. R. Cashman
TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES
Drug Metab. Dispos., July 1, 2003; 31(7): 854 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. Furnes, J. Feng, S. S. Sommer, and D. Schlenk
Identification of Novel Variants of the Flavin-Containing Monooxygenase Gene Family in African Americans
Drug Metab. Dispos., February 1, 2003; 31(2): 187 - 193.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. R. Cashman and J. Zhang
Interindividual Differences of Human Flavin-Containing Monooxygenase 3: Genetic Polymorphisms and Functional Variation
Drug Metab. Dispos., October 1, 2002; 30(10): 1043 - 1052.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.